InflaRx N.V. (IFRX)
NASDAQ: IFRX · Real-Time Price · USD
1.610
+0.030 (1.90%)
May 9, 2025, 1:31 PM - Market open

Revenue by Product

Fiscal year is January - December.
Fiscal Year
FY 2023
Period Ending
Dec '23
Monoclonal Antibodies
68.21K

Revenue by Geography

Fiscal year is January - December.
Fiscal Year
FY 2023
Period Ending
Dec '23
United States
68.21K